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Abstract
Objective: C-peptide is a main outcome measure in treatment trials of diabetes. C-peptide also has a role
in the classiﬁcation of diabetes, which is often difﬁcult in adults and this is also increasingly recognised
in adolescents and elders.
Aim: We aimed to describe the levels of C-peptide in relation to age and body mass index (BMI) in a
large population-based cohort of adults with newly diagnosed diabetes and compare the capabilities of
C-peptide, age and BMI to discriminate between autoimmune and non-autoimmune diabetes.
Subjects and methods: Blood samples from 1180 patients were analysed regarding islet cell antibody,
glutamic acid decarboxylase antibody and fasting C-peptide (FCP). Receiver operating characteristics
(ROC) curves were analysed to check the ability of age, BMI and C-peptide to discriminate between
autoantibody-positive (Ab
C) and -negative (Ab
K) diabetes.
Results: Mean FCP was 0.73G0.5 (range 0.13–1.80) nmol/l in the Ab
C and 1.42G0.9 (range
0.13–8.30) nmol/l in the Ab
K. FCP was 0.02 nmol/l higher per year increase in age at diagnosis
of diabetes. Mean BMI was 26.0G4.8 (range 18.0–39.0) kg/m
2 in the Ab
C and 28.9G5.3 (range
15.5–62.6) kg/m
2 in the Ab
K. FCP increased with age also within each BMI group. The highest
area under the curve (AUC) in the ROC analysis was found for C-peptide, followed by age and BMI
(0.78, 0.68 and 0.66 respectively).
Conclusions: At diagnosis of diabetes, C-peptide was superior to age and BMI in discriminating between
autoimmune and non-autoimmune diabetes. C-peptide increased signiﬁcantlywith BMI andage, latter
alsowithin each BMI group. Most of the adults had normal orhigh levels of C-peptide at presentation of
diabetes among the autoimmune patients.
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Introduction
The importance of level of blood-cell function, measured
as C-peptide, is well recognised in autoimmune diabetes
both through its correlation with endogenous insulin
secretion and in relation to complications (1, 2).A l s oi n
non-autoimmune diabetes, interestinblood-cellfunction
has recently risen considerably (3, 4). Preservation of
blood-cellfunctionafterdiagnosisofdiabetesisnowagoal
also in clinical trials of non-autoimmune diabetes (4, 5).
Classiﬁcation of diabetes at presentation is often
difﬁcult in adults, especially in younger adults (6). The
same difﬁculties are also being increasingly acknowl-
edged in both adolescents and the elderly, where we
found incidences of autoimmune diabetes as high as in
the youngest age groups (7, 8). In addition to a clinical
classiﬁcation based on age, body mass index (BMI),
ketoacidosis and other symptoms, there is also a need
for better tools for classiﬁcation, as type of diabetes has
implications for choice of treatment and long-term
prognosis, including development of complications (9).
Different algorithms aimed to guide physicians in daily
practice regarding classiﬁcation have been published
(10, 11).
Classiﬁcation of diabetes with C-peptide alone was
used in research settings before analysis of antibodies
became prevalent (12). Classiﬁcation based on treat-
ment, a less clear deﬁnition (13, 14), was recommended
by WHO until 1998, when new recommendations
proposed classiﬁcation on aetiological grounds into
mainly autoimmune, or type 1, and non-autoimmune,
or type 2, diabetes (15, 16). The main difference in the
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the rapid and signiﬁcant decrease in endogenous insulin
secretion in autoimmune diabetes compared with non-
autoimmune diabetes, where insulin resistance and
metabolic complications are more pronounced (14, 17).
Objective
The aim of this study was to describe the levels of
C-peptide and BMI, and their relations to age and
antibody status, in a large population-based study of
adults with newly diagnosed diabetes and to explore the
usefulness of C-peptide levels, BMI and age in classi-
ﬁcationofdiabetestypeatdiagnosisofdiabetesinadults.
Subjects and methods
Subjects
A prospective incidence study was performed during
3 years (1998–2001) in Kronoberg county, with
177 000 inhabitants. All the 25 health care centres
and the two hospitals participated. Blood samples were
collected at the time of diagnosis from 98%
(1626/1666) of all newly diagnosed adults aged 18–
100 years (8). The majority of samples, 83%
(1355/1626), were collected in the morning after an
overnight fast. We here report on the fasting C-peptide
(FCP) levels of the 1180/1355 (87%) of the patients
whose data were complete, who were aged R20 years,
with mean age 65.5G14.3, range 20–100 years, and
whose samples were collected %90 days from diagnosis
of diabetes. Of the 1295 fasting subjects with data on
sampling interval, 115 (8.5%) were excluded because
the interval was R91 days, and for 60 subjects (4.5%),
the data were incomplete. Of the 1180 samples reported
here, 56.6% (668) were collected within 10 days,
23.0% (271) within 11–30 days and 20.4% (241)
within 31–90 days. The population was ethnically
homogeneous with 95% Caucasians. Patients with
secondary or gestational diabetes were excluded from
the initial incidence study. There were no signiﬁcant
differences in gender proportions, in the whole material
with 50.7% (598/1180) men, or regarding autoanti-
body-positive (Ab
C) vs -negative (Ab
K), 45% (26/58)
vs 51% (572/1120) men (not signiﬁcant (NS)), or
within the Ab
K or Ab
C groups (PZ0.55–85), or within
the 10-year age groups (PZ0.16–0.70). The study was
approved by the Ethics Committee of Lund University
and performed according to the Declaration of Helsinki.
Methods
C-peptide was centrally analysed at the Department of
Clinical Chemistry, Lund University Hospital, by RIA
(MD315; Euro-Diagnostica AB, Malmo ¨, Sweden).
Detection limit of the method was 0.13 nmol/l, reference
range 0.25–1.0 nmol/l, and total variation (sum of intra-
andinter-assayvariation)was7%.Isletcellantibody(ICA)
levels were analysed with immunoﬂuorescence with a
detection limitof 9 JDF-U, sensitivity100% and speciﬁcity
88%;glutamicaciddecarboxylaseantibody(GADA)levels
were analysed with radioimmunoprecipitation with the
lower reference limit index of 0.08, corresponding to 21
WHO-U/ml, sensitivity of 70% and speciﬁcity of 100%.
BothanalyseswerestandardisedaccordingtotheDiabetes
Antibody Standardization Program (18, 19).
The term autoimmune diabetes (Ab
C) was used if
subjects were positive to at least one of the antibodies to
islet cells and/or glutamic acid decarboxylase. Those
negative for both antibodies were designated non-
autoimmune (Ab
K). Length and weight were measured
by a nurse at the health care centre or hospital
department and not self-reported by the patient. Calcu-
lation of BMIwas possible for 98% of the fasting subjects.
The relationship between FCP and blood glucose level
at the time of sampling for FCP was investigated and the
potential inﬂuence on FCP of being treated with insulin
or oral hypoglycemic agents (OHAs) was also explored,
along with level of blood glucose. Type of OHA was not
recorded, but at least 50%, probably more, ought to
have metformin only, according to the guidelines and
praxis at the time, meaning that !5% of all the newly
diagnosed patients have been possibly treated with
sulphonylurea OHA.
Statistical analyses
Descriptive statistics are reported in 10-year age groups
and ﬁve BMI groups. Differences between groups were
explored by ANOVA, when appropriate with post hoc
Bonferroni correction, and potential interactions
between levels of FCP, BMI, age, autoimmune status
and sample interval (days from diagnosis to sample
collection) were explored. The non-parametric Kruskal–
Wallis and Mann–Whitney U tests and simple and
multiple linear and logistic regression models were also
applied. The sensitivity and speciﬁcity using the
parameters age, BMI and C-peptide, for identifying
autoimmune subjects, were explored by receiver
operating characteristic (ROC) curves. All tests were
two tailed, and a signiﬁcance level of 0.05 was
considered signiﬁcant. SPSS Software (Statistical
Package for the Social Sciences, Chicago, IL, USA)
version 17.0 was used.
Results
C-peptide
In all the fasting subjects with newly diagnosed
diabetes, mean FCP was 1.39G0.9 (range 0.13–8.30)
nmol/l. Mean FCP was signiﬁcantly lower in the newly
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non-autoimmune group (Table 1). There was no
signiﬁcant mean FCP difference with regard to sex in
the Ab
C, but in the Ab
K FCP was higher in the women,
1.48G0.84, compared with the men, 1.37G0.87,
PZ0.03; the range was the same.
The level of FCP increased signiﬁcantly with age at
diagnosis in both non-autoimmune and autoimmune
adults with new diabetes (both P!0.0001; Table 1). For
every 1-year the increase in age in the newly diagnosed,
FCP was 0.02 nmol/l higher in both autoimmune
and non-autoimmune diabetes (both P!0.0001);
for the increase in FCP per 10-year age group, P was
!0.0001 for both diabetes types. For levels of FCP and
BMIperdiagnosis,ageandBMIgroup,seeTables1and2.
Level of FCP at onset of diabetes was independently
inﬂuenced by both age and BMI. Their combined
inﬂuence on the level of FCP was greatest in
autoimmune diabetes: 40% (R
2Z0.398) compared
with 8% (R
2Z0.083) in non-autoimmune diabetes
(P!0.0001 for both). FCP was 0.04 nmol/l higher per
1 kg/m
2 higher BMI in autoimmune and 0.03 nmol/l
higher in non-autoimmune, diabetes (both P!0.001).
Being Ab
C meant a 0.4 nmol/l lower FCP, at the same
levels of age and BMI, compared with the Ab
K subjects
(P!0.001). Mean FCP was correlated to increasing
BMI, and BMI group, and to increasing age, also within
each BMI group, and this was especially apparent in
non-autoimmune diabetes (Fig. 1A).
In the analysis of the three interval groups sampled
(%10 days, within 11–30 days and within 31 to
%90 days) there was no difference in levels of FCP
between any of the three groups among the Ab
K
(1.45G0.9, 1.43G0.86 and 1.31G0.64 nmol/l; NS),
Table 1 Fasting C-peptidelevels (nmol/l), and BMI (kg/m
2), per age group in adults with newly diagnosed diabetes.Values are meanGS.D.;
median, min–max.
C-peptide, fasting BMI
Age
(years) n Autoimmune n
Non-
autoimmune
P,A iv s
non-Ai n Autoimmune n
Non-
autoimmune
P,A iv s
non-Ai
20–29 7 0.32G0.29 13 0.91G0.93 NS 7 23.9G6.2 12 26.1G8.2 NS
0.23, 0.13–0.96 0.66, 0.19–3.5 22.8, 18.0–37.0 22.0, 19.0–42.0
30–39 3 0.18G0.42 28 1.38G0.67 0.05 3 19.0G1.0 27 32.0G7.0 0.04
0.19, 0.13–0.21 1.30, 0.13–3.10 19.0, 18.0–20.0 31.0, 16.5–45.0
40–49 9 0.51G0.31 102 1.16G0.51 !0.0001 9 26.8G6.5 101 31.2G5.2 !0.02
0.52, 0.13–0.96 1.10, 0.13–2.90 24.0, 20.0–39.0 31.0, 19.0–46.0
50–59 14 0.70G0.41 214 1.23G0.58 !0.001 14 26.1G4.7 212 30.5G6.0 !0.008
0.62, 0.24–1.50 1.10, 0.13–5.20 26.4, 19.5–38.0 29.5, 16.4–62.6
60–69 9 1.06G0.62 261 1.30G0.61 NS 9 27.3G3.7 260 29.1G4.5 NS
1.03, 0.13–1.80 1.10, 0.22–4.0 27.5, 22.0–34.0 28.5, 17.7–47.0
70–79 13 0.94G0.53 303 1.55G0.99 !0.03 13 26.8G3.0 296 28.6G5.0 NS
1.10, 0.25–1.80 1.30, 0.13–8.10 27.0, 23.0–33.0 28.0, 15.5–45.5
80C 3 1.25G0.07 199 1.76G1.13 NS 3 28.1G1.9 192 26.2G4.3 NS
1.30, 1.20–1.30 1.40, 0.40–8.30 28.2, 26.0–30.0 25.0, 16.0–47.7
All 58 0.73G0.5 1120 1.42G0.9, !0.0001 58 26.0G4.8 1100 28.9G5.3 !0.0001
0.62, 0.13–1.80 1.20, 0.13–8.30 26.0, 18.0–39.0 28.0, 15.5–62.6
Ai, autoimmune; non-Ai, non-autoimmune.
Table 2 Fasting C-peptide levels (nmol/l), per BMI group (kg/m
2), and age (years) in adults with newly diagnosed diabetes. Values are
meanGS.D., median, min–max.
C-peptide, fasting Age
BMI
group n Autoimmune n
Non-
autoimmune
P Ai vs
non-Ai Autoimmune
Non-
autoimmune
P Ai vs
non-Ai
A !20 7 0.20G0.06 29 1.03G0.64 !0.002 35.6G8.1 63.4G19.8 !0.001
0.22,0.13–0.31 1.0, 0.19–3.60 32.0, 26–50 69.0, 26–95
B2 0 t o !25 20 0.48G0.40 255 1.38G1.1 !0.0001 51.7G17.4 71.7G13.9 !0.0001
0.36,0.13–1.80 1.0, 0.13–8.30 52.0, 22–77 75.0, 23–94
C2 5 t o !30 21 1.09G0.38 440 1.36G0.8 NS 65.1G11.7 66.7G12.3 NS
1.20,0.52–1.80 1.20,0.13–7.80 65.0, 40–82 67.0, 31–94
D3 0 t o !35 6 0.91G0.67 250 1.47G0.7 !0.04 60.3G13.8 62.7G13.3, NS
1.15,0.25–1.80 1.30,0.44–5.30 65.5, 43–73 63.0, 21–96
E R35 4 0.61G0.32 126 1.62G0.8 !0.02 42.3G14.5 59.1G13.9 0.04
0.51,0.35–0.96 1.50,0.13–6.40 42.0, 28–57 58.0, 23–93
All 58 0.76G0.53 1100 1.39G0.84 !0.0001 55.1G16.9 66.1G14.0 !0.0001
0.62, 0.13–1.9 1.20, 0.13–8.3 55.0, 22–82 67.0, 21–100
Ai, autoimmune; non-Ai, non-autoimmune.
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C, FCP was signiﬁcantly lower in the
%10 days sampling, interval (0.57G0.45) compared
with the 31- to 90-day interval (1.19G0.51 nmol/l),
PZ0.02. FCP in the 11- to 30-day group (0.79G
0.47 nmol/l) did not signiﬁcantly differ from any of the
other two interval groups (PZ0.2–0.8). Per increased
interval of 1 day (from 0 to 90 days) from diabetes
diagnosis to sampling, FCP was 0.003 nmol/l lower at
the time of sampling in the Ab
K, PZ0.02; in the Ab
C,i t
was 0.0009 higher, PZ0.004. The corresponding
ﬁgures for BMI were C0.02 kg/m
2 among Ab
K,
PZ0.002, and among Ab
C, C0.08 kg/m
2, PZ0.02.
In the interaction analysis with sample interval only
autoimmunity signiﬁcantly inﬂuenced level of FCP, and
not age nor interval. Sampling interval signiﬁcantly
inﬂuenced level of FCP in the autoimmune subgroup
but had no inﬂuence on FCP in the non-autoimmune
group, conﬁrmed by logistic regression where R
2 for
interval was only 0.04 (4%) in the Ab
K, PZ0.02, and
slightly higher, 0.123 (12%), PZ0.01, in the Ab
C.
Of the 1180 patients, 58 (4.9%) were autoimmune.
Eighty three percent (926/1120) of the Ab
K, 41.4%
(24/58) of the Ab
C and 80.5% of all (950/1180) were
treated with diet only, no insulin or OHAs, at the time of
sampling. In total, 11.7% (138/1180) were treated
with OHAs: for Ab
K patients, this was 11.8%
(132/1120) and for Ab
C33% (19/58). Nine Ab
K and
two Ab
C patients (11/1180, 0.9%) were treated with
both OHA and insulin. Insulin treatment was already
initiated in 7.6% (90/1180) of the patients, 6.3%
(71/1120) Ab
K and 33% (19/58) Ab
C. In the Ab
K,
there were no signiﬁcant differences in the level of mean
FCP between the different treatment groups. FCP levels
were as follows: for diet only, 1.43G0.8; for OHA
treated, 1.36G0.96; for insulin treated, 1.35G1.1; and
for OHACinsulin treated, 1.07G0.57 nmol/l; in the
Ab
C,1 . 0 3 G0.0.47, 0.80G0.49, 0.31G0.22 and
0.33G0.28 nmol/l respectively. In the Ab
C, the insulin
treated had a signiﬁcantly lower mean level of C-peptide
at diagnosis of diabetes than both the diet-only and the
OHA-treated groups (P!0.0001 and 0.01 respect-
ively). Complete data for multiple regression analyses
were available for 88.3% (1042/1180). Mean blood
glucose at sampling (in the 1042 and 1180) was
8.2G2.9 mmol/l (range 1.4–24.2) mmol/l. Only one
subject had blood glucose in the hypoglycemic range,
!3 mmol/l, while 79% (820/1042) had blood glucose
3.0–10.0 mmol/l, 21% (219/1042) 10.1–20.0 mmol/l
and two individuals R20.0 mmol/l.
The relationship between FCP and blood glucose level
at the time of sampling for FCP was explored in a
multiple regression model including age and auto-
immune status. Level of blood glucose had no inﬂuence
at all on level of FCP, PZ0.75. Both age and
autoimmunity, however, inﬂuenced level of C-peptide
signiﬁcantly (P!0.0001). In another multiple
regression model, the potential inﬂuence of blood
glucose on FCP in relation to treatment with insulin
or OHAs at the time of the sampling was calculated.
There was still no correlation between FCP and blood
glucose (PZ0.40), and there were no correlations
between FCP and treatment with OHAs (PZ0.14), but
there was a signiﬁcant relation between being treated
with insulin early and level of FCP (PZ0.001).
BMI and age
Mean BMI for all was 28.8G5.4 (range 15.5–62.6)
kg/m
2. Mean BMI for the Ab
C was signiﬁcantly lower
than that for the Ab
K (P!0.0001; Table 1). The
women had higher mean BMI level than the men, both
the autoimmune, 27.4G5.5 vs 24.5G3.4 kg/m
2
(P!0.03), and the non-autoimmune, 29.4G5.6 vs
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Figure 1 (A) Mean fasting C-peptide (nmol/l), per age and BMI
group in non-autoimmune diabetes. (B) Mean fasting C-peptide,
including 95% conﬁdence intervals, per antibody positivity; all in
adults with newly diagnosed diabetes. **P!0.001.
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2 (P!0.01). For BMI in different age
groups, see Table 1 and Fig. 1A. In the younger adult
age groups, especially ages 30–50 years, among those
who were newly diagnosed with non-autoimmune
diabetes had the highest mean levels of BMI, which
then decreased with increasing age at onset
(P!0.0001). The women were older than the men at
diagnosis of Ab
K diabetes, 66.4G14.5, min 22, max
100 vs 64.1G14.3, min 21, max 94 years (P!0.003).
Mean BMI in the Ab
K did not differ signiﬁcantly from
neither the only GADA
C nor the only ICA
C, nor from
those positive to both antibodies. There were no
signiﬁcant differences in BMI between the different
Ab
C groups.
Autoimmunity
Mean FCP levels in those negative to both antibodies
were signiﬁcantly higher than those positive to both
antibodies (P!0.001), but with correction for multiple
comparisons were not signiﬁcantly different from those
positive to only one antibody, GADA or ICA, and
there were no signiﬁcant differences in the levels of
C-peptide between any of the Ab
C groups (Fig. 1B).
The mean FCP in only GADA
C subjects, 1.06G0.53,
range 0.17–1.80, was lower than that in the Ab
K,
1.42G0.85, range 0.13K8.30, but the difference did
not reach signiﬁcance (Fig. 1B). The majority of the
Ab
C subjects were both GADA
C and ICA
C (Fig. 2A and
B). The Ab
C proportion of newly diagnosed subjects
was highest in the adult age groups below 60 years,
peaking at age 20–29 years (Fig. 2A). The proportion of
Ab
C subjects among the newly diagnosed was 3–5% in
ages 60–100 years. The proportion of newly diagnosed
that was Ab
C decreased with age, but the absolute
numbers of Ab
C subjects were higher in the 50- to
80-year olds than in the younger age groups (Fig. 2B).
Among subjects with BMI %20 kg/m
2, 15–20% were
Ab
C, as were 5–7% among those with BMI 20–
25 kg/m
2 and !5% among BMI R25 kg/m
2.
ROC analysis
ROC curves for the fasting subjects are displayed in
Fig. 3. AUC for FCP was superior to those for age and
BMI for differentiating between Ab
C and Ab
K subjects.
AUC was 0.78G0.04 (0.71–0.85) for C-peptide,
0.68G0.04 (0.61–0.76) for age and 0.66G0.04
(0.59–0.73) for BMI (P!0.0001 for all). For sensitivity
and speciﬁcity, see Fig. 3.
35
10
6
4
3 3 2
31
8
6
4
2 3 2
31
10
8 7
3
5
3
35
12
8 7
4 5
3
20–29 30–39 40–49 50–59 60–69 70–79 80+
Age group
20–29 30–39 40–49 50–59 60–69 70–79 80+
Age group
ICA +
Both +
GAD +
Any Ab +
B
A
0
5
10
15
20
25
0%
5%
10%
15%
20%
25%
30%
35%
40%
Figure 2 Prevalence of antibodies per age group in percent (A) and
absolute numbers (B) in adults with newly diagnosed diabetes.
Fasting C-peptide (nmol/l) Sensitivity (%) Specificity (%)
0.50 96 40
0.60 94 51
0.70 89 66
0.80 83 61
0.90 76 65
1.00 66 71
Age (years)
40 97 18
50 87 34
55 77 53
BMI (kg/m
2)
23.0 87 27
24.0 81 44
25.0 74 47
1.0
0.8
0.6
0.4
0.2
0.0
0.0 0.2 0.4 0.6
1-Specificity
S
e
n
s
i
t
i
v
i
t
y
C-peptide
Age
BMI
Source of the curve
ROC curve
0.8 1.0
Figure 3 ROC analysis of C-peptide,
BMI and age to identify subjects that are
autoimmune.
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C-peptide
C-peptide level at diagnosis of both autoimmune and
non-autoimmune diabetes increased with age at onset,
which has been described, mostly in younger patients
(20). Similar to our ﬁndings, FCP increased by 2% per
year from age at onset in newly diagnosed Italian type 1
patients aged 0–49 years (21). Of our newly diagnosed
adults above the age of 40 years with autoimmune
diabetes, 95% had detectable C-peptide compared with
60% in the 15- to 34-year olds in the Diabetes Incidence
Study in Sweden (22). The same trend was found in
non-diabetic subjects and was experimentally demon-
strated to be due to increasing insulin resistance with
age independent of BMI (23). Our elderly patients had
higher FCP than those healthy elders, probably due
to a dominating insulin resistance at onset of diabetes
(23, 24, 25).
C-peptide at diagnosis was increased with increasing
BMI level and also with age within each BMI group,
emphasising the independent inﬂuence of age on
C-peptide. The women had higher levels of BMI and
were older at presentation of Ab
K diabetes than the
men, and consequently also had higher C-peptide levels
compared with the men. Men are usually more prone to
abdominal and visceral rather than subcutaneous fat
distribution, and visceral fat is not as well reﬂected by
BMI (26, 27).
The Botnia study found signiﬁcantly lower levels of
FCP than we did, 0.46 vs 0.62 nmol/l, in GADA
C vs
GADA
K patients (17); the levels showed the same
relation but both lower than ours, probably due to the
longer duration of diabetes that was 6G10 years, while
in the Kronoberg study, all patients were recently
diagnosed. Our levels of C-peptide may differ from
those found in other studies due to differences in age, as
we also included the eldest age groups, in which
diabetes is most prevalent (8, 28, 29, 30). In contrast
to the prevailing notion that level of blood glucose
inﬂuences level of peptide, we found no evidence of such
inﬂuence in this cohort. A minority of the patients in
this study were treated with OHAs or insulin at the time
of the study, and treatment was withheld on the
morning of the fasting sampling, therefore it is not
likely that these factors had any major inﬂuence on the
results. The majority of the patients (88%) were treated
with diet only at the time of sampling for FCP, and it was
only in the already insulin-C-treated Ab
C patients that
there was a signiﬁcant correlation between level of
blood glucose at sampling and level of FCP (PZ0.003).
Body mass index
Our ﬁndings that the most obese subjects were affected
by non-autoimmune diabetes earlier in life than the less
obese were in accordance with a registry study from
Oregon (31). The levels of BMI that we found were lower
than those in the Oregon study, but higher than those in
the Botnia study, probably due to differences in
ethnicities and duration after onset of diabetes (17,
31). The trend of negative correlation between BMI and
age in Ab
K diabetes was similar in the Botnia study. We
also analysed this relation in patients with Ab
C diabetes
and found an opposite trend. This, in combination with
that the majority of the adults with newly diagnosed
diabetes, independently of presence of autoantibodies,
had BMI in the overweight or obese ranges, accentuates
the limitation in using BMI for distinction between
diabetes types. The ROC analysis ranked BMI after both
C-peptide and age regarding ability to detect auto-
immune diabetes. In accordance with this, one study
found that a combination of antibodies and C-peptide
was found to have the highest predictive value for
ketose-prone diabetes (32). The explanatory rate for
C-peptide level of age and BMI was greater in
autoimmune than in non-autoimmune diabetes, 39 vs
8%. This indicates that the major explanations are due
to other factors and that the relations between insulin
resistance and blood-cell function are more complex,
which has also been demonstrated experimentally (33).
Autoimmunity
Considering that we also included the oldest age groups,
with most prevalent diabetes, the prevalence of patients
positive to at least one pancreatic autoantibody was in
accordance with previous studies, such as UKPDS and
the Botnia study (8, 17, 34). Some early studies
analysed only one antibody (17, 28, 29, 34). The
differences in frequency of Ab
C between studies can be
explained by the number and types of antibodies
analysed, duration of diabetes as well as ages in the
populations studied.
The proportion of Ab
C subjects among our newly
diagnosed patients decreased with age and was 3–5% in
ages 60–100 years. However, the absolute numbers of
subjects positive to at least one antibody was higher in
the 50- to 80-year olds than in the younger adult age
groups due to the larger number of individuals affected
by diabetes in the older age groups (8).
Classiﬁcation
Age and BMI are among the most frequently used tools
for clinical classiﬁcation but seldom tested in an
evidence-based manner. In our large population-based
cohort of newly diagnosed patients, we found that,
while still not ideal, C-peptide was a better discriminator
than both age and BMI for identifying those positive to
at least one of GADA and/or ICA, and C-peptide AUC
reached the same level in ROC analysis as several
classiﬁcation schemes for ketosis-prone diabetes (32).
The reasons for assigning individuals with diabetes
to different subgroups are both to facilitate research
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treatments and prevention and for clinical use when
recommending treatment to patients (35, 36). Con-
comitantly, there are also limitations to the use of
classiﬁcations (37).
The emergence of different treatments for different
types of diabetes, reactualised by the latest new group of
anti-diabetic drugs, the incretin-based therapies and
by treatments aiming for prevention, relief and cure of
autoimmune diabetes, all put new focus on blood-cell
function (4, 5, 38), which is still best estimated by
C-peptide (39). C-peptide is available in standard
commercial assays, is not very costly and ought to be
readily available in many settings.
Previously, the difﬁculties of classiﬁcation and thereby
of recommending the optimal treatment and follow-up
for patients were identiﬁed to be problems of young
adults, but now it appears as a problem of all ages,
not least in the elderly, where diabetes is most frequent
(7, 8).
Autoantibodies predict insulin dependency within
3–6 years in the majority of adult patients diagnosed
with diabetes (34, 40). In the latest recommendation by
WHO, LADA is considered a variant of autoimmune,
or type 1 diabetes (15, 16), and many share that view
(36, 41, 42), but it is also debated (37). A useful
classiﬁcation of diabetes type can save time, effort and
concern, and thereby costs, for health care providers
and patients; it may increase patient security and
possibility of empowerment and minimise risks (30, 32,
41, 43). As the number of adults with autoimmune
diabetes are larger than those diagnosed with auto-
immune diabetes during childhood, many patients are
affected (8, 44). They have a decreasing blood-cell
function and are at risk of ketoacidosis. Delay of insulin
treatment and prolonged time with deteriorated blood
glucose involves risk of earlier debut of complications
(9, 32, 41, 45, 46).
Conclusions
C-peptide level at diagnosis of diabetes was superior to
both age and BMI in discriminating between auto-
immune and non-autoimmune diabetes; it increased
with increasing BMI, and age, and later even within
each BMI group. Analysis of C-peptide is less expensive
than antibody analyses and better than both BMI and
age at indicating autoimmune diabetes, information
that affects both choice of treatment and follow-up;
therefore, C-peptide can be a good complement in
clinical practice in many settings.
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